Member Info for Laura2022

New CEO is transforming this company AND more news to come as shown in the recent interviews

Both FAB PYC

1 generating large revenues relatove to market cap FAB half year £1.2mln half year v £5mln cap , PYC £1mln half year V £1.4mln

2 Both have cash

3 forefront of AI improving drug discovery

4 good, honest BODs

5 near to profitability in 2025

6 benefitting from UK grant funding

7 tiny market caps ( £5mln and £.14mln) versus peers on AIM

Tricky

More contracts

This will do a FAB

Thank you for your email – I will pass on your feedback to the Company.

 

In terms of current plans, you can safely assume that the Company’s activities outlined in the September interims remains the case – continuing to progress enrolment in its B2B2C agreement with the large US health plan, pursuing partnerships with pharmaceutical companies as Trellus expands its verticals into patient support programs and clinical trials, It is worth noting as well that in the last 6 months Trellus has strengthened its Board with the additions of Kevin Murphy and Brian Griffin, both of whom have significant experience in the US healthcare industry.

 

Any material updates on the above or other areas of the business will be announced via RNS – would you like me to add you to our distribution list for Trellus so that you receive any news directly from us going forwards?

 

Kind regards,

Slowly edging up since purchases

Another positive day

Well away from those mid 70s

Even better

Let us know few mins BEFORE you sell which is yours

Looking forward

Please.let us know which imaginary sale is yours

More in common than you're prepared to admit as doesn't suit your agenda

Both FAB PYC

1 generating large revenues relatove to market cap FAB half year £1.2mln half year v £5mln cap , PYC £1mln half year V £1.4mln

2 Both have cash

3 forefront of AI improving drug discovery

4 good, honest BODs

5 near to profitability in 2025

6 benefitting from UK grant funding

7 tiny market caps ( £5mln and £.14mln) versus peers on AIM

So

You sold a share (pyc) that you never owned as per your tirade of misinformation over the last 3mths

$7bln market and PYC at the forefront in the words of PYC Ceo

Antibody-drug conjugates (ADCs) are transforming oncology by offering a precise, targeted approach to treatment. Combining the specificity of monoclonal antibodies with the potency of cytotoxic agents, ADCs are designed to selectively target cancer cells while reducing systemic toxicities compared to traditional therapies. As ADCs advance through clinical trials, each phase contributes essential insights into their safety, efficacy, and therapeutic potential. 

The global ADC market has experienced significant growth, with a valuation of $7.35 billion in 2022. Projections indicate this market will exceed $28 billion by 2028, reflecting a compound annual growth rate (CAGR) of 25.4% during the forecast period from 2022 to 2028. This expansion is driven by the increasing prevalence of cancer, advancements in ADC technologies, and a growing pipeline of ADC candidates in clinical development

Thanks Trench

Moneybags

Happy to give a quick summary of course

The greenfilter box i assume is the stalker jamrock

Happy with the reply

Starting to have a real affect now there are no seller

1 hour ago

Physiomics plc

1,749 followers

1h  Edited

How can predictive modelling improve chemotherapy outcomes? Our latest poster shares findings from the PARTNER trial, validating our precision dosing tool for guiding the use of docetaxel and reducing the risk of neutropenia. Check out the poster at: https://lnkd.in/e4a-n3dJ #Oncology #PKPD #ClinicalTrials #PrecisionDosing

More than Suzy, Satu etc out together

Director/PDMR Subscription

As set out in the announcement of 9 December 2024, Mark Eccleston, CEO of the Company has informed the Company that, in addition to his participation in the Subscription, he has subscribed for a further 3,076,923 Broker Offer Shares under the Broker Offer. Details of his shareholdings following completion of the Fundraising and subject to shareholder approval at the General Meeting, are set out below:

Interesting point pj

Delayed buys ?

Moved back up on very little

We already have several grant funding projects so would be not surprising to see more from the various life science funding schemes annihced in the budget budget in October

We also have the increasing relationship with NASDAQ listed DoseMeRx to fully integrate our dosing software into their full clinical portfolio

(Click on KingHomer posts on this forum)